Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipragliflozin in type 2 diabetes mellitus with nonalcoholic fatty liver disease
jRCTs071180069Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ipragliflozin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Astellas Pharma. Started Aug 2015; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCTs071180069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180069.